Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.
Mark N. Stein
Consultant or Advisory Role - Pfizer
Research Funding - Amgen; Exelixis; ImClone Systems; Lilly; Merck; Novartis; Pfizer; Roche/Genentech
Laura Quan Man Chow
Research Funding - ImClone Systems
David C. Smith
Research Funding - ImClone Systems
Dale Randall Shepard
Research Funding - ImClone Systems
Ding Wang
Research Funding - ImClone Systems
John D. Powderly
Employment or Leadership Position - BioCytics (U)
Consultant or Advisory Role - Amplimmune; AstraZeneca; Bristol-Myers Squibb; Genentech; Lilly; Merck
Stock Ownership - BioCytics
Honoraria - Bristol-Myers Squibb; Dendreon; Genentech
Research Funding - Amplimmune; AstraZeneca; Genentech; Lilly; Merck; Millennium; Progenics
Ling Gao
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Yong Lin
Employment or Leadership Position - Lilly
Minori Koshiji
Employment or Leadership Position - Lilly
Stock Ownership - Lilly